SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

A reported Binance security breach has fueled Bitcoin selling and weighed on MSTR, which traders view as a leveraged proxy for Bitcoin; the discussion also centers on Strategys Q3 revenue miss, earnings driven largely by Bitcoin valuation gains, and its CFO transition. Bears warn of further downside and dilution, while bulls characterize the drop as a buying opportunity.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare add-on reimbursement could fall after the first quarter of 2027 has fueled concerns about CorMedixs pricing and revenue, alongside a sharp selloff. Traders disagree on how much weight to give DaVitas preliminary outlook, with some pointing to CMSs published reimbursement estimate while others see ongoing pressure ahead.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A run to a fresh 52-week high ahead of the upcoming Q3 report has traders focused on BRIUMVIs sales ramp and managements outlook; some point to earnings expectations, while others speculate about an unconfirmed buyout and short covering.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

Energy-sector strength and concern over oil-supply disruptions tied to Middle East tensionsespecially risks to shipping and refiningdominate the discussion around XLE. Traders point to the rally and energys relative strength as bullish, while others warn that diplomatic progress, profit-taking, or an overextended move could weigh on the fund.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Attention is focused on upcoming Q3 results and the Casgevy sales update, with traders debating whether rising patient starts and treatment-center expansion will translate into stronger collaboration revenue. The upcoming CTX310 clinical presentation is another key catalyst; sentiment is mixed between anticipation of data-driven progress and concern about the stocks decline and CFO transition.

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

Energy Transfers strong quarterly results and outlook are fueling discussion of its potential to benefit from rising natural-gas demand for AI data centers and other power customers. Many traders are bullish on that growth and the distribution, while others are frustrated that the unit price has not responded more strongly.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 77,177.65528711 USD and is down -1.08 over the last 24 hours. It is currently trading on 12773 active market(s) with $46,266,908,298.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoin is drawing attention amid a reported major Binance security breach, with traders debating whether shaken confidence in exchanges and possible withdrawals could add selling pressure. Others argue Bitcoin has held up relatively well and view the decline as a buying opportunity, while the breachs broader impact remains uncertain.

Select Sector SPDR Trust (The) - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

XLK is drawing attention amid a sharp technology-sector selloff, with traders citing broad technical breakdowns and weakness in semiconductors and other tech groups. The conversation is mostly bearish, though some see the pullback as a potential buying opportunity or expect a bounce; confirmation of support remains a key debate.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbases post-earnings selloff is drawing attention as traders weigh weak underlying crypto-trading activity and a revenue shortfall against headline profitability, much of which they attribute to gains on crypto holdings. A Bitcoin slide and Binance hack concerns are adding pressure, though some traders view the decline as an overreaction or buying opportunity.

Quantinuum Inc. is a quantum computing platform that offers solutions like hardware platforms, developer tools, application libraries and solution-targeted intellectual property (“IP”). The company was founded on January 20, 2026 and is headquartered in Broomfield, CO.

Quantinuum Inc. - Ordinary Shares - Class A

Quantinuum Inc.

Concern about the Nov. 30 IPO lockup expiration and potential insider selling is weighing on QNT, alongside a sharp selloff. Traders are split between expecting continued pressure and arguing that Quantinuums technical progress, Oracle partnership and federal funding support the longer-term case.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026

Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, announced today that, on October 20, 2026, the Company will implement a 1-for-7 reverse split of its common stock. The...

Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that it has selected Avance Clinical, a full-service contract research organization (CRO) with global...

REVB Stock Drops 10% After Company Announces Third Reverse Split In A Year

Equity

Revelation Biosciences said its 1-for-4 reverse stock split will become effective from January 28, 2026.

Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours?

Revelation Biosciences shares jumped after the FDA agreed that a single Phase 2/3 study could support an application for its acute kidney injury treatment.read more...

Revelation Biosciences Stock Slides 17% After Company Reports 3 Severe Adverse Events In Early Stage Trial Of Inflammation Drug

The firm also reported that Gemini significantly reduced inflammatory activity in the trial and restored normal cellular response to stimuli.


Revelation Biosciences Stock Sinks 12% After Reverse Split Reveal; Retail Traders Eye ‘Bigger News’

The company is nearing completion of enrollment in its Phase 1b Gemini trial for CKD, with topline results expected shortly. 

FTSE 100 today: BoE rate decision looms; Vodafone names CFO; Whitbread reports

Investing.com -- British stocks opened lower on Thursday as investors looked ahead to the Bank of England’s rate decision, with markets broadly anticipating no change in interest rates at the meeting.

Frasers Group decides not to make offer for Revolution Beauty

Investing.com -- Frasers Group PLC (LON:FRAS) said on Thursday that it will not make an offer for a U.K.-based cosmetics and skincare retailer   Revolution Beauty Group   PLC (LON:REVB).

Frasers explores potential bid for Revolution Beauty, company confirms

Carmell, Mustang Bio, Revelation Biosciences Dominate Retail Biotech Talk As 2025 Kicks Off

From acquisition news and FDA designations to fresh optimism for struggling stocks, these biotechs piqued Stocktwits users the most on the first trading day of 2025.


This account has been verified as an official REVB representative.

Verified Account

Revelation Biosciences

Revelation Biosciences, Inc. engages in the development of immunologic-based therapies for the prevention and treatment of disease. Its product candidates include REVTx-99b, its lead therapeutic candidate being developed for allergic rhinitis and chronic nasal congestion, REVDx 501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation, and REVTx 200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. The company was founded on November 20, 2019 and is headquartered in San Diego, CA.

Revelation Biosciences Inc

Bearish Sentiment

<ul class="summary-bullets"><li>This marks Revelation Biosciences’ third reverse stock split over the past year.</li><li>Last week, the company said it would exercise outstanding warrants to purchase up to 13.1 million shares for gross proceeds of $11 million.</li><li>The company also reached an agreement with the U.S. Food and Drug Administration on an approval pathway for Gemini as a treatment for acute kidney injury.</li></ul>Shares of Revelation Biosciences, Inc. (REVB) fell more than 10% on Monday after the company announced it will implement a 1-for-4 reverse stock split effective Jan. 28, 2026.REVB stock will begin trading on a post-split basis the same day under the existing ticker symbol. The move is aimed at boosting the share price to regain compliance with Nasdaq’s minimum bid price requirement.<h2 class="st-heading-2">Third Reverse Split In A Year</h2>This marks Revelation Biosciences’ third reverse stock split over the past year. The company implemented a one-for-sixteen reverse split on Jan. 28, 2025, followed by a <a href="https://stocktwits.com/news-articles/markets/equity/revelation-biosciences-stock-sinks-12-after-reverse-split-reveal-retail-traders-eye-bigger-news/chF0d3xRT4H">1-for-3 reverse stock split</a>, which became effective on July 5, 2025.Last week, the company entered into an agreement to exercise certain outstanding warrants to purchase up to 13.1 million shares at a discounted exercise price of $0.86 per share, for gross proceeds of $11 million.Separately on January 21, Revelation reached an agreement with the U.S. Food and Drug Administration (FDA) on an approval pathway for Gemini as a treatment for acute kidney injury (AKI). The FDA agreed that a single well-controlled adaptive Phase 2/3 clinical study involving about 300 patients could support a new drug application. The study will use a composite endpoint of death and/or need for dialysis and is designed to transition from dose-finding to confirmatory testing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp intraday decline, retail sentiment on Stocktwits remained in the ‘extremely bullish’ territory amid ‘extremely high’ message volumes.One Stocktwits user expects REVB stock to fall under $0.5.<stembedurl>https://stocktwits.com/Donniechen12345/message/642885351</stembedurl>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/hl-stock-surges-on-silver-record-rally-despite-lower-2026-outlook/cmy7YCcR4hR">Hecla Mining Forecasts Lower 2026 Silver Output – But HL Stock Rises On Record Silver Rally</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$4.03
Prev Close	$3.75
Open	$3.76
Dividend Yield	0.00%
50-Day Moving Average	$5.77
Beta	0.55
Avg. Volume	3,759.53
PE Ratio	-0.05

52-Week High	$40.60
52-Week Low	$3.08
Market Capitalization	$2.29M
EPS (Annual)	-$167.62
Price to Book	0.22
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

REVB Fundamentals